Toggle Main Menu Toggle Search

Open Access padlockePrints

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Lookup NU author(s): Dr Yvette DrewORCiD

Downloads


Licence

This is the authors' accepted manuscript of an article that has been published in its final definitive form by American Association for Cancer Research, 2020.

For re-use rights please refer to the publisher's terms and conditions.


Abstract

©2019 American Association for Cancer Research.PURPOSE: Tissue factor (TF) is a potential target in cervical cancer, as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody-drug conjugate targeting TF, has demonstrated encouraging activity in solid tumors. Here we report data from the cervical cancer cohort of innovaTV 201 phase I/II study (NCT02001623). PATIENTS AND METHODS: Patients with recurrent or metastatic cervical cancer received tisotumab vedotin 2.0 mg/kg every 3 weeks until progressive disease, unacceptable toxicity, or consent withdrawal. The primary objective was safety and tolerability. Secondary objectives included antitumor activity. RESULTS: Of the 55 patients, 51% had received ≥2 prior lines of treatment in the recurrent or metastatic setting; 67% had prior bevacizumab + doublet chemotherapy. Fifty-one percent of patients had squamous cell carcinoma. The most common grade 3/4 treatment-emergent adverse events (AEs) were anemia (11%), fatigue (9%), and vomiting (7%). No grade 5 treatment-related AEs occurred. Investigator-assessed confirmed objective response rate (ORR) was 24% [95% confidence interval (CI): 13%-37%]. Median duration of response (DOR) was 4.2 months (range: 1.0+-9.7); four patients responded for >8 months. The 6-month progression-free survival (PFS) rate was 29% (95% CI: 17%-43%). Independent review outcomes were comparable, with confirmed ORR of 22% (95% CI: 12%-35%), median DOR of 6.0 months (range: 1.0+-9.7), and 6-month PFS rate of 40% (95% CI: 24%-55%). Tissue factor expression was confirmed in most patients; no significant association with response was observed. CONCLUSIONS: Tisotumab vedotin demonstrated a manageable safety profile and encouraging antitumor activity in patients with previously treated recurrent or metastatic cervical cancer.


Publication metadata

Author(s): Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau H-T, Machiels J-P, Spicer JF, Jones R, Forster MD, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL

Publication type: Article

Publication status: Published

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Year: 2020

Volume: 26

Issue: 6

Pages: 1220-1228

Print publication date: 15/03/2020

Online publication date: 03/12/2019

Acceptance date: 26/11/2019

Date deposited: 18/04/2020

ISSN (print): 1078-0432

ISSN (electronic): 1557-3265

Publisher: American Association for Cancer Research

URL: https://doi.org/10.1158/1078-0432.CCR-19-2962

DOI: 10.1158/1078-0432.CCR-19-2962

PubMed id: 31796521


Altmetrics

Altmetrics provided by Altmetric


Share